ArticleProceedings of the National Academy of Sciences of the United States of America2013
Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 90 citations in OpenAlex.
- First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers.Clinical and translational science · 2022Trial
- Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study.Probiotics and antimicrobial proteins · 2018Trial
- Trial
- Antibodies targeting HSV glycoprotein B require effector functions to protect neonatal mice.Journal of virology · 2026Article
- Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection.bioRxiv : the preprint server for biology · 2026Article
- Eliminating interactions with the viral Fc receptor improves antibody-mediated protection against neonatal HSV infection in mice.Science translational medicine · 2025Article
- Prefusion structure, evasion and neutralization of HSV-1 glycoprotein B.Nature microbiology · 2025Article
- A potent protective bispecific nanobody targeting Herpes simplex virus gD reveals vulnerable epitope for neutralizing.Nature communications · 2025Article
- Viral immunological complications in neurological surgery: A comprehensive review of homeostatic disturbances and cognitive impairments.Surgical neurology international · 2025Review
- Harnessing the potency of scorpion venom-derived proteins: applications in cancer therapy.Bioresources and bioprocessing · 2024Review
- Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus.Journal of biomedical science · 2024Article
- Ligand-based drug design against Herpes Simplex Virus-1 capsid protein by modification of limonene through in silico approaches.Scientific reports · 2024Article
- Therapeutic Potential of Biochanin A in Herpes Simplex Keratitis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Effects of Melatonin Alone or Associated with Acyclovir on the Suppressive Treatment of Recurrent Genital Herpes: A Prospective, Randomized, and Double-Blind Study.Biomedicines · 2023Article
- A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice.The Journal of clinical investigation · 2023Article
- Cell-to-cell spread inhibiting antibodies constitute a correlate of protection against herpes simplex virus type 1 reactivations: A retrospective study.Frontiers in immunology · 2023Article
- Engineering antiviral immune-like systems for autonomous virus detection and inhibition in mice.Nature communications · 2022Article
- Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity.The Journal of experimental medicine · 2022Article
- Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections.Frontiers in immunology · 2022Review
- Advancing Our Understanding of Corneal Herpes Simplex Virus-1 Immune Evasion Mechanisms and Future Therapeutics.Viruses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the availability of antiviral chemotherapy, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections remain a severe global health problem. Of particular concern is the growing incidence of drug resistance in immunocompromised patients, which stresses the urgency to develop new effective treatment alternatives. We have developed a humanized monoclonal antibody (mAb hu2c) that completely abrogates viral cell-to-cell spread, a key mechanism by which HSV-1/2 escapes humoral immune surveillance. Moreover, mAb hu2c neutralized HSV fully independent of complement and/or immune effector cell recruitment in a highly efficient manner. Prophylactic and therapeutic administration of mAb hu2c completely prevented infection-related mortality of severely immunodeficient mice being challenged with a lethal dose of HSV-1. The high neutralization capacity of mAb hu2c was fully maintained toward clinical HSV isolates being multiresistant to standard antiviral drugs, and infection was fully resolved in 7/8 nonobese diabetic/SCID mice being infected with a multidrug resistant HSV-1 patient isolate. Immunohistochemical studies revealed no significant cross-reactivity of the antibody toward human tissues. These features warrant further clinical development of mAb hu2c as an immunotherapeutic compound for the management of severe and particularly drug-resistant HSV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.